In the pivotal ATHENA outcomes trial, MULTAQ achieved the combined primary endpoint of time to CV hospitalization or death from any cause — a reduction entirely attributable to reduction in CV hospitalization. MULTAQ reduced the primary endpoint by 24% vs placebo (P<0.0001).¹